Pioglisant (30 mg) Pioglitazone > He hoʻomaʻemaʻe a me ke pale aku

Nā Papa 15 mg, 30 mg

Aia ma ka papa papa

mea waiwai - pioglitazone hydrochloride 16.53 mg (e like me ka pioglitazone 15.00 mg) no ka inane no ka 15 mg, a i ka 33.06 mg (30.00 mg) no kahi laʻana o 30 mg,

nā mea hoʻowalewale: lactose monohydrate, kalma carmellose, hydroxypropyl cellulose, magnesium stearate.

Ke keʻokeʻo a ʻāpana paha keʻokeʻo nā papa, e hoʻopuni ai me kahi papa biconvex (no ke kauʻana he 15 mg), he keʻokeʻo a kokoke paha ke keʻokeʻo, nā ʻāpana, nā kihi, nā kime me ka bevel a me kahi hōʻailona ma ke ʻano o ke kea (no kahi dute no 30 mg).

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau

Hoʻohui ka ʻike o ka pioglitazone a me nā pākuhi hoʻōla i loko o ka serum koko ma ke kiʻekiʻe kiʻekiʻe 24 mau hola ma hope o hoʻokahi pae wai. Ua hoʻohua ʻia nā paʻila serilibrium o ka pioglitazone a me ka heluna pioglitazone (pioglitazone + a me nā metabolite ikaika) i loko o 7 mau lā. ʻAʻole alakaʻi ke alakaʻi i ka hōʻuluʻulu ʻana o nā pūhui a i ʻole nā metabolits. ʻO ka kukuna nui loa i ka serum (Cmax), ka wahi ma lalo o ka pihi (AUC) a me ka hōʻemi haʻahaʻa loa i ka serum koko (Cmin) o ka pioglitazone a me ka hoʻonui pioglitazone e hoʻonui i ka pā i nā dosis o 15 mg a 30 mg i kēlā me kēia lā.

Ma hope o ka lawelawe waha, ua lawe koke ʻia ka pioglitazone mai ka gastrointestinal tract, i hoʻoholo ʻia i loko o ke koko serum ma hope o 30 mau minuke, a hiki i ka ʻike kiʻekiʻe ma hope o 2 mau hola. He kūʻokoʻa o ka hoʻopau ʻana i ka lāʻau. ʻO ka bioavailability piha loa ma mua o 80%.

ʻO ka nui o ka puʻuwai o ka hāʻawi ʻana i ka lāʻau i loko o ke kino he 0.25 l / kg. ʻO Pioglitazone a me kāna mau metabolite hoʻoikaika e pili nui ana i nā protein plasma (> 99%).

Hāpai ʻO Pioglitazone e hoʻopili nui ʻia e ka hydroxylation a me ka oxidation, a ua hoʻololi pū ʻia ka metabolites i nā glucuronide a i ʻole konate sulfate. ʻO nā metabolites M-II a me M-IV (hydroxy derivatives o ka pioglitazone) a me M-III (keto derivatives o ka pioglitazone) i hana i ka lāʻau lapaʻau.

Hoʻopili i ka pioglitazone, ʻo M-III a me M-IV nā mea nui e pili ana i ka lāʻau lapaʻau i ʻike ʻia i loko o ka serum o ke kanaka ma hope o ka hoʻohana mau ʻana i ka hopena. Ua ʻike ʻia ʻo ka nui isoforms o ka cytochrome P450 e komo i ka metabolism o pioglitazone. Ka hana ka metabolism i ka isoforms cytochrome P450 e like me CYP2C8 a, i kahi liʻiliʻi, CYP3A4, me ka komo hou ʻana o nā isoforms ʻē aʻe, e komo pū ana me CAIP1A1.

Ma hope o ka lawelawe waha, ma kahi o 45% o ka loaʻa ʻana o ka pioglitazone e loaʻa i ka urine, 55% i loko o ka feces. Ka hoʻōki o nā pioglitazone ma o ke akea i kala ʻole ʻia, ʻoi loa ka ʻano o nā metabolites a me ko lākou conjugates. ʻO ka hapalua hapalua o ka pioglitazone o 5-6 mau hola, he pioglitazone keu (pioglitazone + metabolites ikaika) ʻo 16-23 hola.

Nā hui ahonui kūikawā

ʻO ka hapalua hapalua o ka pioglitazone mai ka serum koko e hoʻomau i ka loli ʻole i ka poʻe maʻi me ka hoʻonaninani (ʻo ka cleinine clearance 30-60 ml / min) a koʻikoʻi (ʻo ka cleinine clearance 4 ml / min). ʻAʻohe ʻike e pili ana i ka hoʻohana ʻana i ka lāʻau lapaʻau no ka mālama ʻana o nā mea maʻi i hoʻomālamalama ʻia, no laila ʻaʻole pono e hoʻohana ʻo Pioglisant e mālama i kēia ʻano maʻi.

ʻO ka hana hema ʻoleHoʻopilikia ka Pioglisant i nā maʻi me nā nele o ka ate.

ʻO ka wehewehe ʻana i ka hana pharmacological

Hoʻowaliwaleʻi maikaʻi ia i nā receptors gamma i hoʻoneʻe ʻia e ka proliferator peroxisome (gamma PPAR). Hoʻololi ia i ka hoʻohalike o nā genes e pili ana i ka insulin a komo i ka kaohi o ke kūpaʻa o ka glucose a me ka lipid metabolism i loko o ka adipose, ka mōʻīpū a me nā puʻupaʻa. ʻAʻole ia e hoʻoulu i ka ulu o ka insulin, eia nō naʻe, ke hoʻoikaika nei ia i ka wā e mālama ʻia ka hana o ka insulin-synthetic o ka pancreas. Hoʻēmi i ka pale ʻana o ka insulin i nā kiko peripheral a me ka leʻa, hoʻonui i ka ʻai o nā glucose i hilinaʻi ʻia o ka insulin, e hōʻemi ana i ka pae o ka glucose mai ka ate, e hoʻoneʻe ana i ka pae o glucose, insulin a me ka hemoglobin glycosylated i loko o ke koko. I nā mea maʻi me ka protein metabolism maʻi ʻole, e hōʻemi ana ia i ka triglycerides a hoʻonui i ka HDL me ka ʻole o ka hoʻololi ʻana o ka LDL a me ka kolamu holoʻokoʻa.

Ma nā hoʻokolohua hoʻokolohua, ʻaʻohe ona ka maʻi carcinogenic a me nā mutagenic. Ke hoʻolako ʻia i nā lā wahine a me nā kāne a i ka 40 mg / kg / lā, pioglitazone (a he 9 mau kiʻekiʻe ma mua o ka MPDC, helu ʻia ma 1 m2 o ka ʻōpū o ke kino), ʻaʻohe hopena i ka hānai.

Nā hōʻailona no ka hoʻohana ʻana

Kauka 2 diabetes mellitus:
- i ka maʻi manuahi ma nā mea maʻi me ka momona nui a me ka kīʻaha ʻole maikaʻi ʻole a me ka hoʻomaʻamaʻa ʻana me ka naʻau ʻole e hui ai i ka metformin a i ʻole ka hele ʻana o nā contraindications no kāna hoʻohana.
- ma ke ʻano o ka hui pū ʻana:

1. me ka metformin i nā mea maʻi me ke kaupaona ʻana me ka loaʻa ʻole o ka mana glycemic kūpono ma ke ala o ka metformin monotherapy,
2. Me nā derivatives sulfonylurea i loko o nā mea maʻi wale nō ka hoʻohālikelike ʻana o ka metformin, i ka ʻike ʻole ʻana o ka mana glycemic kūpono e kū nei i ka mana o ka monotherapy me nā derivatives sulfonylurea.
3. me ka insulin o ka ʻole o ka lawa glycemic kūpono i ka wā hana me ka insulin i nā mea maʻi no ka metformin he contraindicated.

Lapaʻau lāʻau

Thiazolidinedione hypoglycemic agent no ka hoʻohana waha.

Hoʻohālikelike ʻo Pioglitazone i nā ʻenehana neʻe i loko o ka pūlima, hoʻāla ʻia e ka peroxisome proliferator (PPARγ). Hoʻololi ia i ka hoʻohalike o nā genes ka mea e pili ana i ka insulin a komo i ka kaohi o ke kūlohelohe o ke koko a me ka lipid metabolism i loko o ka adipose, ka mōʻīpū a me nā puʻuwai. ʻAʻole e like me nā mākaukau i loaʻa mai nā sulfonylureas, ʻaʻole i hoʻoulu ʻia ka pioglitazone i ka huna ʻana i ka insulin, akā e hana ʻia ana i ka wā i mālama ʻia ka hana insulin-synthetic o ka pancreas. Hoʻopili ʻo Pioglitazone i ka pale ʻana o ka insulin i nā kōpita peripheral a me nā leʻa, hoʻonui i ka ʻai o nā glucose i hilinaʻi i ka insulin a e hōʻemi i ka hoʻokuʻu ʻana o ka glucose mai ka ate, e hoʻoneʻe ana i ka kūpaʻa o ka glucose, insulin a me ka hemoglobin glycosylated. I ka wā o ka maʻi me ka pioglitazone, ʻo ka piʻi ʻana o ke kukuna o ka triglycerides a me nā momona momona i loko o ke kōʻai koko, a laila e piʻi aʻe ka nui o ke kiʻekiʻe lipoproteins kiʻekiʻe.

No nā mea maʻi me ka maʻi diabetes type 2, hoʻomaikaʻi ʻia ke kāohi koko glucose i kēlā me kēia ʻōpū ʻole a ma hope o ka ʻai ʻana.

Lapaʻau lāʻau

ʻO Pioglitazone ka wikiwiki i hoʻopili koke ʻia, ʻo Cmax o ka pioglitazone i loko o ke koko koko e hōʻemi pinepine ʻia 2 mau hola ma hope o ka lawelawe waha. I ka loaʻa ʻana o nā dosis therapeutic, hoʻonui ʻia ke kukuna me ka hoʻonui nui ʻana. Me ka hoʻokele pinepine ʻana o ka cumulation, pioglitazone a me nā metabolites ʻaʻole i ʻike ʻia. ʻAʻohe ʻai i ka ʻai ʻana. ʻO Bioavailability o kahi 80%.

ʻO Vd ka 0.25 l / kg ka nui o ke kino a ua loaʻa iā 4-7 mau lā ma hope o ka hoʻomaka ʻana o ka hōʻola. ʻO ka paa ʻana o nā protein plasma o ka pioglitazone ma mua o 99%, kona mau metabolites - ʻoi aku ma mua o 98%.

Hoʻomili ʻia ka Pioglitazone e ka hydroxylation a me ka okoa. ʻO ka hapanui, ua hele kēia kaʻina me ke komo ʻana o nā isoenzymes cytochrome P450 (CYP2C8 a me CYP3A4), a me ke ʻano liʻiliʻi, ʻokoʻa nā pualena ʻē aʻe. 3 mai 6 o nā koho metabolites (M) hōʻike i ka hana lāʻau lapaʻau (M-II, M-III, M-IV). Hāʻawi ʻia i ka hana pharmacological, ʻoliʻoli a me ka palena o ka hoʻopaʻa ʻana i ka protein plasma, pioglitazone a me ka metabolite M-III e hoʻoholo like ana i ka hana holoʻokoʻa, ka hāʻawi ʻana o ka metabolite M-IV i ka hana nui o ka lāʻau lapaʻau ma kahi o 3 mau manawa nui aʻe ma mua o ka hāʻawi ʻana o ka pioglitazone, a me ka hana pili o ka metabolite M-II he liʻiliʻi . ^ E Ha yM.

Ua hōʻike i nā haʻawina vitro ua pioglitazone ʻaʻole i pale i ka isoenzymes o CYP1A, CYP2C8 / 9, CYP3A4.

Hoʻokuʻu ʻia ia ma o nā ʻāpana, a me nā pūnanu (15-30%) i ke ʻano o nā metabolites a me kā lākou conjugates. ʻO T1 / 2 o ka pioglitazone i loli ʻole mai ka wai koko plasma he 3-7 mau hola, a no nā metabolites ikaika 16-24 mau hola.

Ke kūpaʻa nei o nā pioglitazone a me nā metabolite ikaika i ka plasma koko i kahi kiʻekiʻe kiʻekiʻe no 24 mau hola ma hope o ke kaha hoʻokahi o ka maʻi o kēlā me kēia lā.

ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā

ʻO nā mea maʻi a ʻelima a i ʻole me ka hana ʻē ʻole i hoʻopiha ʻia, ʻaʻole pono ke hoʻoponopono ʻia.

E kū'ē i ke kua o ke ake o ka hana aho, ua ʻoi aku ka nui o ka pioglitazone manuahi.

Hoʻohana no ka hana renal impaired

No nā mea maʻi me ka hana renal impaired (clearance clearance nui ma mua o 4 ml / min), ʻaʻole koi ʻia ka hoʻoponopono ʻana. ʻAʻohe ʻikepili ma ka hoʻohana ʻana i ka pioglitazone i nā mea maʻi e loaʻa ana i ka mālama hemodialysis. No laila, ʻaʻole pono e hoʻohana ʻia ka pioglitazone ma kēia pūʻulu o nā maʻi.

- hikiʻole ke kaulike i ka renal (CC ma mua o 4 ml / min).

Nā Hoʻohui

- momo type diabetes
- kehi ketoacidosis,
- ka puʻuwai puʻuwai, me ke komo mōʻaukala (ka papa o ka I-IV e like me ka helu ʻana o NYHA).
- ka hana kaulike (hoʻonui i nā hana o nā ateʻalima 2.5 mau manawa ma mua o ka palena kiʻekiʻe o ka maʻamau),
- ka maʻi kaulike o ka maʻi renalole (CC ma mua o 4 ml / min),
- ka nele o ka lactase, lactose intolerance, glucose-galactose malabsorption,
- ka wahine hāpai
- wā lactation,
- ʻaʻole i mālama ʻia nā keiki ma lalo o ka 18 mau makahiki (nā haʻawina haʻalulu no ka palekana a me ka hana pono o ka pioglitazone ma nā keiki),
- Hypersensitivity i pnoglitazone a i ʻole nā meaʻokoʻa o ka lāʻau lapaʻau.

Me ka mālama aka - edematous syndrome, anemia.

Hoʻohana i ka wā hāpai a me ka lactation. ʻO ka mea kūpono a me ka palekana o ka pioglitazone i nā wahine hāpai, ʻaʻole i aʻo ʻia, no laila, contraindicated e hoʻohana i ka lāʻau i ka wā hāpai. Ua hōʻike ʻia ʻo Pioglitazone e lohi i ka ulu ʻana o ka fetal. ʻAʻole ʻike ʻia inā ua excreted ʻo ka pioglitazone i ka umauma umauma, no laila, ʻaʻole e lawe ʻia ka lāʻau lapaʻau e nā wahine i ka wā lactation. Inā kūpono, ʻo ke koho ʻana o ka lāʻau i ka wā lactation, ʻo ka hōʻuluʻulu ʻana o ka waʻa e hoʻopau ʻia.

Nā hopena hopena

Mai nā naʻau sensory: pinepine - ʻike i ka ʻike.

Mai ka papa hana hanu: pinepine - ka maʻi o ka hanu o ke kino, pinepine - sinusitis.

Mai ka ʻaoʻao o ka metabolism: pinepine - hoʻonui i nā paona kino.

Mai ka pūnaehana nūhou: pinepine - hypesthesia, pinepine - i ʻole nā insomnia.

ʻO ka hui pū ʻana o ka pioglitazone me ka metformin

Mai nā ʻōpū hemopoietic: pinepine - anemia.

Mai nā naʻau sensory: pinepine - ʻike i ka ʻike.

Mai ka pūnaehana ʻana: pinepine - mau lemulewa.

Mai ka ʻaoʻao o ka metabolism: pinepine - hoʻonui i nā paona kino.

Mai ka ʻōnaehana musculoskeletal: pinepine - arthralgia.

Mai ka pūnaehana hoʻoliʻuku: pinepine - nui ke poʻo.

Mai ka ʻōnaehana genitourinary: pinepine - hematuria, erectile dysfunction.

Ke hoʻohui ʻana o ka pioglitazone me ka sulfonylureas

Mai nā naʻau sensory: pinepine - vertigo, ʻike maka.

Mai ka pūnaehana ʻana: pinepine - mau lemulewa.

Nā mea'ē aʻe: pinepine - nā luhi.

Mai ka ʻaoʻao o ka metabolism: pinepine - hoʻonui i ke kaumaha o ke kino, pinepine - hoʻonui i ka hana o ka dehydrogenase lactate, hoʻonui nui momona, hypoglycemia.

Mai ka ʻōnaehana o ka manawa: pinepine - dizziness, pinepine - ʻeha o ke poʻo.

Mai ka ʻōnaehana genitourinary: pinepine - glucosuria, proteinuria.

Mai ka ʻili: pinepine - hoʻonui ʻia.

ʻO ka hui pū ʻana o ka pioglntazone me metformin a me ka sulfonylureas

Mai ka ʻaoʻao o ka metabolism: pinepine pinepine - hypoglycemia, pinepine - hoʻonui i ke kaumaha o ke kino, hoʻonui i ka hana o ka phosphokinase (CPK).

Mai ka ʻōnaehana musculoskeletal: pinepine - arthralgia.

ʻO ka hui pū ʻana o ka pioglitazone me ka insulin

Mai ka ʻaoʻao o ka metabolism: pinepine - hypoglycemia.

Mai ka ʻōnaehana musculoskeletal: pinepine - eha ʻeha, arthralgia.

Mai ka papa hana hanu: pinepine - ka manawa pokole o ka hanu, bronchitis.

Mai ka pūnaehana cardiovascular: pinepine - iʻe ʻole ka naʻau.

Nā ʻokoʻa: pinepine - edema.

Ma ka ʻaoʻao o nā ʻāpana sensory: ʻaʻole i maopopo ka ʻike i ka neʻe ʻana - ka ʻaʻe ʻana o ka macula, kaʻa o ka iwi.

Me ka hoʻohana mau ʻana o ka pioglitazone no ka ʻoi aku o ka 1 makahiki i ka 6-9% o nā hihia, nā maʻi me nā edema, ʻōmaʻomaʻo a maʻalahi ʻole, ʻaʻole pono ia e hoʻolimalima i ka hopena.

ʻO nā hauna keu ʻike pinepine ʻia i ka hoʻomaka ʻana o ka lāʻau a kau ʻia me ka loli o ka neʻe ʻana o ka glucose glucose, e like me nā mea ʻē aʻe hypoglycemic.

ʻLoe a me ke kākele

I loko o 1 mau manawa / e pili ana i ka 'ai o ka meaʻai.

ʻO nā hōʻai a hoʻomaka ʻia he 15 a 30 mg 1 mau manawa / ʻO ka nui o ka nui o kēlā me kēia lā no monotherapy ka 45 mg, me ka hui pū 30 mg.

Ke koho nei i ka pioglitazone e hui pū me ka metformin, hiki ke hoʻomau i ka hoʻomohala ʻana i ka metformin i ka hopena like.

I ka hui pū ʻana me nā derivatives sulfonylurea: i ka hoʻomaka o ka mālama ʻana, hiki ke hoʻomau ko lākou hoʻokele ma ka hopena like. I ka hihia o ka hypoglycemia, makemake ʻia ka hoʻohaʻahaʻa ʻia o ka derogative sulfonylurea.

I ka hui pū me ka insulin: ʻo ka pioglitazone mua o ka maʻi mua he 15-30 mg /, ke kū nei ka nui o ka insulin a e hōʻemi paha i ka 10-25% inā hele mai ka hypoglycemia.

No nā poʻe maʻi maʻi, ʻaʻole pono ka hoʻoponopono ʻana o ka inika.

ʻAʻole pono e hoʻohana ʻo Pioglitazone i nā mea maʻi me ka hana pūlima.

ʻAʻohe ʻikepili e pili ana i ka hoʻohana ʻana o ka pioglitazone i nā mea maʻi ma lalo o ka 18 makahiki o laila, no laila, ʻaʻole i kauoha ʻia ka hoʻohana ʻana o ka pioglitazone ma kēia kau makahiki.

ʻO ka pilina me nā lāʻau lapaʻau ʻē aʻe

Ke hoʻohana nei i ka pioglitazone e hui pū me nā lāʻau lapaʻau hypoglycemic waha, hiki i ka hoʻomohala ʻana o ka hypoglycemia. I kēia hihia, pono paha e hoʻemi ʻia ka nui o ka lāʻau lapaʻau hypoglycemic waha.

E kū'ē i ke kua o ka hoʻohana ʻana o ka pioglitazone me ka insulin, hiki ke hoʻomohala ʻia ka hōʻemi o ka puʻuwai.

ʻAʻole pili ʻo Pioglitazone i ka pharmacokinetics a me nā pharmacodynamics o glipizide, digoxin, warfarin, metformin.

Hoʻonui ka Gemfibrozil i ka waiwai o AUC o ka pioglitazone 3 mau manawa.

Hoʻopuka ʻo Rifampicin i ka metabolism o ka pioglitazone e 54%.

I loko vitro ketoconazole pale i ka hana o ka papa o pioglitazone.

Nā ʻōlelo kikoʻī kūikawā no ke komo ʻana

Ke mālama nei i ka diabetes mellitus type 2, i ka lawe ʻana i ka pioglitazone, loia ia e ukali i kahi meaʻai a me ka hana e mālama ai i ka hopena o ka lāʻau lapaʻau, a me ka pili me ka hiki o ka hoʻonui ʻana i ke kaumaha o ke kino.

Me ka hoʻohana ʻana o ka pioglitazone, hiki ke mālama ʻia i ka nui o ka wai o ka plasma, hiki iā ia ke alakaʻi i ka hoʻomohala a hōʻiliʻili ʻana o ka puʻuwai puʻuwai, no laila, inā e piʻalolo ka ʻāina o ka ʻōnaehana cardiovascular, e hoʻohuli ai ka pioglitazone.

ʻO ka poʻe maʻi e loaʻa i kahi liʻiliʻi o ke kumu no ka hoʻoulu ʻana o ka puʻuwai naʻau maʻamau (CHF) e hoʻomaka i ka mālama ʻana me ka puʻupuʻu liʻiliʻi a hoʻonui ʻia hoʻi. He mea pono i ka manawa kūpono e ʻike i nā hōʻailona mua o ka hōʻeha o ka puʻuwai, hōʻemi ke kaumaha (e hōʻike paha i ka hoʻolālā ʻana o ka hōʻeha o ka naʻau) a i ʻole ka hoʻomohala ʻana o ka edema, ka mea nui i nā mea maʻi me ka hōʻemi o ka hopena cardiac. I ka hihia o ka hoʻonui ʻana o ka CHF, ua hoʻopau koke ka lāʻau.

Hiki i Pioglitazone ke hana i ka hana luhi i ka nele. Ma mua o ka mālama ʻana a me ka manawa i ka wā o ka ʻoihana, pono e ʻike ʻia ka hana o ka enzyme. Inā ʻoi aku ka hana ALT ma mua o 2 mau manawa ʻoi aʻe ka palena o ka maʻamau, a i ʻole ma mua o nā hōʻailona ʻē aʻe o ka hina o ka ate, ua contraindicated ka hoʻohana ʻana o ka pioglitazone.Inā, ma 2 mau haʻawina hoʻokolohua, ʻoi loa ka hana a ALT ma mua aʻe o ka palena palena o ka maʻamau ma ka manawa 3 a i ʻole ka hoʻomanawanui e hoʻomanawanui i ka jaundice, hoʻopau koke ka mālama ʻana me ka pioglitazone. Inā loaʻa i ka mea maʻi nā hōʻailona e kuhikuhi ana i ka hana o ka puʻuwai hemahema (hiki ʻole ke ʻano, ka luaʻi, ka ʻōpū o ka ʻōpū, nā nāwaliwali, anorexia, nā ʻeleʻeleʻeleʻele), pono e ʻike koke ʻia ka hana o nā huina o ka huina.

Hiki i Pioglitazone ke hoʻoemi i ka hemoglobin a i ka hematocrit paha e ka 4% a me ka 4.1%, kēlā, e kū ana ma ka hemodilution (ma muli o ka hoʻomauʻana o ka wai).

Hoʻonui ʻo Pioglitazone i ka hoʻonaninani ʻana i ka iwi i ka insulin, e hoʻonui ai i ka nui o ka hypoglycemia i loko o nā mea maʻi e loaʻa ana i ka hui hoʻohui pū ʻia e pili ana i ka derogatives sulfonylurea a i ʻole insulin. E koi paha i ka hōʻemi ʻana o ka hopena o ka hopena.

Hiki i Pioglitazone ke hōʻeha a hoʻonāukiuki paha i ka macular edema, ke alakaʻi i kahi hōʻemi i ka ʻike acuity.

Hiki paha i Pioglitazone ke hoʻonui i ka ulu ʻana o nā mea i hoʻohaki ʻia i nā wahine.

I nā maʻi me ka maʻi polycystic ovary syndrome, ʻo ka nui o ka ulu ʻana o ka nui o ka insulin e alakaʻi i ka hoʻomaka hou o ka ovulation a me ka hāpai ʻana paha. ʻO nā maʻi me ka polycystic ovary syndrome i makemake ʻole e lilo i ka hānai e pono ia e hoʻohana i nā ala kūpono o ka contraception. Inā hiki i ka wā hānau, pono e hoʻokuʻu koke ʻia ka mālama ʻana.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a kāohi i nā mīkini

Hāʻawi i nā hopena kūpono o ka lāʻau lapaʻau, pono e mālama pono i ka wā o ka hoʻokele ʻana i nā kaʻa a me ka hana ʻana me nā kīʻaha e pono ai ka paʻa ʻana.

Pehea e hoʻohana ai: dosis a me ke ʻano o ka mālama ʻana

E lawe waha i 1 ka manawa i ka lā, me ke ʻano o ka hoʻokomo ʻana o ka meaʻai.

ʻO nā papa hoʻomaka ʻana he 15 a 30 mg hoʻokahi i kēlā me kēia lā. ʻO ka palena kiʻekiʻe loa o kēlā me kēia lā no 45 monote, he 45 mg me ka hui pū ʻana - 30 mg.

I ke koho ʻana iā Piouno i ka hui me ka metformin, hiki ke hoʻomau i ka hoʻomohala ʻana i ka metformin ma ka mauʻu like.

I ka hui pū me ka insulin: ʻo ka pioglitazone mua o ka maʻi mua he 15-30 mg i kēlā me kēia lā, hoʻomau ʻia ka nui o ka insulin a e hōʻemi paha ma ka 10-25% inā hele mai ka hypoglycemia.

No nā poʻe maʻi maʻi, ʻaʻole pono ka hoʻoponopono ʻana o ka inika.

ʻAʻole pono e hoʻohana ʻo Pioglitazone i nā mea maʻi me ka hana pūlima.

ʻAʻohe ʻikepili e pili ana i ka hoʻohana ʻana o ka pioglitazone i nā mea maʻi ma lalo o ka 18 makahiki o ka makahiki, ʻaʻole ʻoluʻolu ʻia ka hoʻohana ʻana o ka pioglitazone i kēia makahiki.

Ka hana lāʻau lapaʻau

ʻO ka hana ikaika a Piouno he pioglitazone, kahi mākaʻikaʻi hypoglycemic o ka hana thiazolidinedione no ka hoʻokō waha.

Hoʻohālikelike ʻo Pioglitazone i nā ʻāpana gamma i loko o ke kinipona, hoʻāla ʻia e ka peroxisome proliferator (PPAR gamma). Hoʻololi ia i ka hoʻohalike o nā genes ka mea e pili ana i ka insulin a komo i ka kaohi o ke kūlohelohe o ke koko a me ka lipid metabolism i loko o ka adipose, ka mōʻīpū a me nā puʻuwai. ʻAʻole e like me nā mākaukau i loaʻa mai nā sulfonylureas, ʻaʻole i hoʻoulu ʻia ka pioglitazone i ka huna ʻana i ka insulin, akā e hana ʻia ana i ka wā i mālama ʻia ka hana insulin-synthetic o ka pancreas. Hoʻopili ʻo Pioglitazone i ka pale ʻana o ka insulin i nā kōpita peripheral a me nā leʻa, hoʻonui i ka ʻai o nā glucose i hilinaʻi i ka insulin a e hōʻemi i ka hoʻokuʻu ʻana o ka glucose mai ka ate, e hoʻoneʻe ana i ka kūpaʻa o ka glucose, insulin a me ka hemoglobin glycosylated. I ka wā o ka maʻi me ka pioglitazone, ʻo ka piʻi ʻana o ke kukuna o ka triglycerides a me nā momona momona i loko o ke kōʻai koko, a laila e piʻi aʻe ka nui o ke kiʻekiʻe lipoproteins kiʻekiʻe.

No nā mea maʻi me ka maʻi diabetes type 2, hoʻomaikaʻi ʻia ke kāohi koko glucose i kēlā me kēia ʻōpū ʻole a ma hope o ka ʻai ʻana.